Rise in the number of patients suffering from non-Hodgkin’s lymphoma is the factor responsible for the growth of non-Hodgkin’s lymphoma therapeutics market.
Faster cure rates with the deployment of modern-day non-Hodgkin’s lymphoma therapeutics are also bolstering the market. Non-Hodgkin’s lymphoma is a kind of cancer starting with lymphatic system (the body’s germ-fighting system).
The companies operating in the non-Hodgkin’s lymphoma therapeutics market are launching new drugs, and also conducting clinical trials to upgrade their existing products. They are exploring the probability of devising cost-effective drugs in order to widen the consumer base in the low-income geographies.
Non-Hodgkin’s lymphomas are amongst the commonly occurring lymphomas, and could prove to be fatal if not treated effectively. Numerous clinical trials are being conducted by the key participants to develop new non-Hodgkin’s lymphoma treatment course, particularly for refractory and relapsed forms.
Numerous key players, emerging as well as established, are investing in new drug launches and developing pipeline candidates. This inclination is owing to a large patient pool that needs precise and aggressive modes of cancer in the later stages of their lives.
However, higher costs associated with some kinds of therapies like immunotherapies may restrain the non-Hodgkin’s lymphoma therapeutics market going forward.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Higher incidence of various types of cancer that also constitute non-Hodgkin’s lymphomas is boosting the non-Hodgkin’s lymphoma therapeutics market. Certain non-Hodgkin’s lymphomas are pretty aggressive with respect to their nature and need a precise treatment plan.
Positive and better clinical outcomes generally occur owing to administration of advanced and efficient non-Hodgkin lymphoma treatment products. Numerous cancers generally show no symptoms till cancer reaches advanced stages. In such scenarios, efficient and aggressive therapeutics are required for better clinical outcomes.
Factors mentioned above are thus driving the urge to delve deeper into NHL therapeutics.
Extensive R&D activities regarding development of efficient therapeutics for various kinds of non-Hodgkin lymphomas are amongst the key factors driving the non-Hodgkin’s lymphoma therapeutics market.
Rise in sophistication of diagnostic techniques has resulted in early diagnosis of numerous NHLs, which, in turn, results in better patient prognosis.
As per the American Cancer Society, the year 2020 witnessed close to 77,240 individuals in the U.S. getting diagnosed with one or the other form of non-Hodgkin’s lymphoma. However, research states that Burkitt’s lymphoma can be treated if detected on time.
Positive cure rates are bound to draw more patients toward adoption of therapeutics in this regard.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest non-Hodgkin’s lymphoma therapeutics market analysis, North America led the lymphoma targeted therapies landscape in 2023 and the scenario is expected to persist during the forecast period.
This is attributed to the U.S. witnessing a higher prevalence of all forms of cancer including various types of blood cancers such as non-Hodgkin’s lymphoma. This trend has resulted in adoption of expensive forms of therapies for treating various forms of non-Hodgkin’s lymphomas like immunotherapies.
Europe is witnessing launch of CAR T-cell therapies, which is helping it to grow in the non-Hodgkin’s lymphoma therapeutics market. Asia Pacific’s significant growth regarding the lymphatic cancer therapeutic approaches is due to regulatory approvals of therapeutics such as KYMRIAH (tisagenlecleucel) in Japan.
The key participants in the non-Hodgkin’s lymphoma therapeutics market are conducting clinical trials regarding new products to strengthen their position.
For instance, in December 2020, AstraZeneca announced that its cancer drug called Calquence meant for treating mantle cell lymphoma patients received positive responses at the time of Phase II clinical trial.
Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., GSK plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AbbVie Inc., AstraZeneca plc, and Johnson & Johnson Pvt. Ltd. are some of the key players covered in the non-hodgkin's lymphoma therapeutics market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 8.0 Bn |
| Market Forecast (Value) in 2034 | US$ 18.6 Bn |
| Growth Rate (CAGR) | 8.0% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 8.0 Bn in 2023
It is projected to grow at a CAGR of 8.0% from 2024 to 2034
Growing prevalence of non-Hodgkin lymphomas and stronger cure rates
Hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., GSK plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AbbVie Inc., AstraZeneca plc, and Johnson & Johnson Pvt. Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Non-Hodgkin’s Lymphoma Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, by Treatment Therapy
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Therapy, 2020-2034
6.3.1. Chemotherapy
6.3.2. Targeted Therapy
6.3.3. Immunotherapy
6.3.4. Others (Radiation Therapy, etc.)
6.4. Market Attractiveness, by Treatment Therapy
7. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, by Indication Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication Type, 2020-2034
7.3.1. B-Cell Lymphomas
7.3.2. T-Cell Lymphomas
7.4. Market Attractiveness, by Indication Type
8. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness, by Route of Administration
9. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by End-user
10. Global Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Therapy, 2020-2034
11.2.1. Chemotherapy
11.2.2. Targeted Therapy
11.2.3. Immunotherapy
11.2.4. Others (Radiation Therapy, etc.)
11.3. Market Attractiveness, by Treatment Therapy
11.4. Market Value Forecast, by Indication Type, 2020-2034
11.4.1. B-Cell Lymphomas
11.4.2. T-Cell Lymphomas
11.5. Market Attractiveness, by Indication Type
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Oral
11.6.2. Parenteral
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Treatment Therapy
11.11.2. By Indication Type
11.11.3. By Route of Administration
11.11.4. By End-user
11.11.5. By Country
12. Europe Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Therapy, 2020-2034
12.2.1. Chemotherapy
12.2.2. Targeted Therapy
12.2.3. Immunotherapy
12.2.4. Others (Radiation Therapy, etc.)
12.3. Market Attractiveness, by Treatment Therapy
12.4. Market Value Forecast, by Indication Type, 2020-2034
12.4.1. B-Cell Lymphomas
12.4.2. T-Cell Lymphomas
12.5. Market Attractiveness, by Indication Type
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Oral
12.6.2. Parenteral
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Treatment Therapy
12.11.2. By Indication Type
12.11.3. By Route of Administration
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Therapy, 2020-2034
13.2.1. Chemotherapy
13.2.2. Targeted Therapy
13.2.3. Immunotherapy
13.2.4. Others (Radiation Therapy, etc.)
13.3. Market Attractiveness, by Treatment Therapy
13.4. Market Value Forecast, by Indication Type, 2020-2034
13.4.1. B-Cell Lymphomas
13.4.2. T-Cell Lymphomas
13.5. Market Attractiveness, by Indication Type
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Oral
13.6.2. Parenteral
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Treatment Therapy
13.11.2. By Indication Type
13.11.3. By Route of Administration
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Therapy, 2020-2034
14.2.1. Chemotherapy
14.2.2. Targeted Therapy
14.2.3. Immunotherapy
14.2.4. Others (Radiation Therapy, etc.)
14.3. Market Attractiveness, by Treatment Therapy
14.4. Market Value Forecast, by Indication Type, 2020-2034
14.4.1. B-Cell Lymphomas
14.4.2. T-Cell Lymphomas
14.5. Market Attractiveness, by Indication Type
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Oral
14.6.2. Parenteral
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Treatment Therapy
14.11.2. By Indication Type
14.11.3. By Route of Administration
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Therapy, 2020-2034
15.2.1. Chemotherapy
15.2.2. Targeted Therapy
15.2.3. Immunotherapy
15.2.4. Others (Radiation Therapy, etc.)
15.3. Market Attractiveness, by Treatment Therapy
15.4. Market Value Forecast, by Indication Type, 2020-2034
15.4.1. B-Cell Lymphomas
15.4.2. T-Cell Lymphomas
15.5. Market Attractiveness, by Indication Type
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Oral
15.6.2. Parenteral
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Treatment Therapy
15.11.2. By Indication Type
15.11.3. By Route of Administration
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Mylan N.V.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Teva Pharmaceutical Industries Ltd.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Sanofi S.A.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Pfizer Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. GSK plc
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Novartis AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Bayer AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Eli Lilly and Company
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Merck & Co., Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. AbbVie Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. AstraZeneca plc
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Johnson & Johnson Pvt. Ltd.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
List of Tables
Table 01: Global Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 02: Global Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 03: Global Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 05: Global Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 06: North America Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 07: North America Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 08: North America Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 9: North America Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 10: North America Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 11: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 13: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 14: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 15: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 16: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 18: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 19: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 20: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 23: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 24: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 25: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 26: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 28: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 29: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 30: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn), by Region, 2023 and 2034
Figure 02: Global Non-Hodgkin’s Lymphoma Therapeutics Market Revenue (US$ Bn), by Treatment Therapy, 2023
Figure 03: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value Share, by Treatment Therapy, 2023
Figure 04: Global Non-Hodgkin’s Lymphoma Therapeutics Market Revenue (US$ Bn), by Indication Type, 2023
Figure 05: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value Share, by Indication Type, 2023
Figure 06: Global Non-Hodgkin’s Lymphoma Therapeutics Market Revenue (US$ Bn), by Route of Administration, 2023
Figure 07: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value Share, by Route of Administration, 2023
Figure 08: Global Non-Hodgkin’s Lymphoma Therapeutics Market Revenue (US$ Bn), by End-user, 2023
Figure 09: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value Share, by End-user, 2023
Figure 10: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value Share, by Region, 2023
Figure 11: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value (US$ Bn) Forecast, 2020-2034
Figure 12: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 13: Global Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 14: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 15: Global Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 16: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 17: Global Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 18: Global Non-Hodgkin’s Lymphoma Therapeutics Market Revenue (US$ Bn), by End-user, 2023
Figure 19: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value Share, by End-user, 2023
Figure 20: Global Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
Figure 21: Global Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 22: North America Non-Hodgkin’s Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 23: North America Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
Figure 24: North America Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
Figure 25: North America Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 26: North America Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 27: North America Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 28: North America Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 29: North America Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 30: North America Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 31: North America Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 32: North America Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 33: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 34: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 37: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 38: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 39: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 41: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 42: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 43: Europe Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 44: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 45: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 46: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 47: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 48: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 49: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 50: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 52: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 53: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 54: Asia Pacific Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 55: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 56: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 57: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 58: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 59: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 60: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 61: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 62: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 63: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 64: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 65: Latin America Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 68: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 69: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 70: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 71: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 72: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 73: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 74: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 75: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 76: Middle East & Africa Non-Hodgkin’s Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Non-Hodgkin’s Lymphoma Therapeutics Market
